Latest Breaking News On - Blood therapeutics chief executive ted love - Page 1 : comparemela.com

The New York drugmaker is buying Global Blood Therapeutics, which sells a drug for sickle-cell disease and has two in development. It will pay $68.50 per share.

Albert bourlaPfizer incAmgen incGlobal blood therapeutics incChemocentryx incGlobal blood therapeuticsWall street journalYork based pfizerChief executive albert bourlaSouth san franciscoBlood therapeutics chief executive ted loveWall street